title: [Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
abstract: Most targeted anticancer therapies induce dermatological toxicities that are often predominant. In particular, pigmentary changes are frequent and relatively characteristic, and they present most often as depigmentation. In this review, we describe the main pigmentary disorders observed with these new therapies, which affect the skin, hair, nails and mucous membranes. Hyperpigmentation secondary to MEK or EGFR inhibitors will be described, as well as forms of hypopigmentation specific to several tyrosine kinase inhibitors (imatinib, sunitinib and pazopanib), blue dots induced by vandetanib, and eruptive naevus triggered by RAF inhibitors. Vitiligoid reactions to CTLA4 and PD1/PD-L1 blocking agents will also be described.
authors.affiliation: Service de dermatologie, institut Claudius-Regaud, centre de lutte contre le cancer, 20-24, rue du Pont Saint-Pierre, 31052 Toulouse, France. sibaud.vincent@claudiusregaud.fr
authors.forename: V
authors.initials: V
authors.lastname: Sibaud
authors.forename: C
authors.initials: C
authors.lastname: Robert
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides / Q000009:adverse effects; D000068818:Cetuximab; D000069439:Dasatinib; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D000068877:Imatinib Mesylate; D007191:Indazoles; D007211:Indoles / Q000009:adverse effects; D000074324:Ipilimumab; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives; D010671:Phenylurea Compounds / Q000009:adverse effects; D010859:Pigmentation Disorders / Q000139:chemically induced*; D010879:Piperazines / Q000009:adverse effects; D010880:Piperidines / Q000009:adverse effects; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D011743:Pyrimidines / Q000009:adverse effects; D011758:Pyrroles / Q000009:adverse effects; D011799:Quinazolines / Q000009:adverse effects; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D000077157:Sorafenib; D013449:Sulfonamides / Q000009:adverse effects; D000077210:Sunitinib; D013844:Thiazoles / Q000009:adverse effects
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001549:Benzamides; D007191:Indazoles; D007211:Indoles; D000074324:Ipilimumab; C105992:PDCD1 protein, human; D010671:Phenylurea Compounds; D010879:Piperazines; D010880:Piperidines; D061026:Programmed Cell Death 1 Receptor; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D011799:Quinazolines; D013449:Sulfonamides; D013844:Thiazoles; D009536:Niacinamide; C516667:pazopanib; D000068877:Imatinib Mesylate; D000077157:Sorafenib; D066246:ErbB Receptors; D040262:Receptors, Vascular Endothelial Growth Factor; C498826:nilotinib; D000068818:Cetuximab; D000069439:Dasatinib; D000077210:Sunitinib; C452423:vandetanib